Intel stock spikes after report of possible US government stake
Investing.com -- Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) shares surged 17.6% after the RNAi therapeutics company reported second-quarter earnings that significantly exceeded analyst expectations, driven by strong sales of its ATTR amyloidosis treatments.
The company posted adjusted earnings of $0.32 per share for the quarter ended June 30, 2025, dramatically outperforming the analyst consensus estimate of -$0.59. Revenue reached $773.7 million, substantially above the $643.2 million analysts had projected. Total (EPA:TTEF) net product revenues increased 64% YoY to $672.2 million, primarily fueled by AMVUTTRA’s performance in ATTR cardiomyopathy.
"Our first full quarter of AMVUTTRA sales in ATTR-CM provided a significant inflection in our TTR franchise revenues, with total net product revenues growing 64% year-over-year," said Yvonne Greenstreet, CEO of Alnylam. "While still early in the launch, we are very encouraged by the initial pace of uptake."
AMVUTTRA’s sales reached $492 million, up 114% YoY, while the company’s rare disease drugs GIVLAARI and OXLUMO generated combined revenues of $127.7 million, representing 24% growth compared to the same period last year.
Following these strong results, Alnylam raised its 2025 total net product revenue guidance to $2.65-$2.8 billion, up from the previous range of $2.05-$2.25 billion. This represents expected growth of 61-70% compared to 2024.
The company continues to advance its pipeline, with the TRITON-CM Phase 3 trial of nucresiran in ATTR-CM underway and two additional Phase 3 trials expected to start this year. Alnylam also announced that nucresiran has received Fast Track Designation from the FDA for the treatment of ATTR cardiomyopathy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.